Concepedia

Publication | Closed Access

A PILOT TRIAL OF RECOMBINANT HUMAN INTERLEUKIN-10 IN KIDNEY TRANSPLANT RECIPIENTS RECEIVING OKT3 INDUCTION THERAPY1,2

DOI

54

Citations

47

References

1997

Year

Karl Martin Wissing, Emmanuel Morélon, Christophe Legendre, Luc De Pauw, Alexandre LeBeaut, Paul Grint, Margaret Maniscalki, Brigitte Ickx, Pierre Vereerstraeten, Lucienne Chatenoud,
Transplantation

Abstract

Pretreatment with doses of up to 1 microg/kg rhIL-10 is safe and reduces the release of TNF-alpha induced by OKT3. However, higher doses might promote early sensitization to OKT3.

References

YearCitations

Page 1